These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11489947)

  • 21. Downstream of kinase, p62(dok), is a mediator of Fc gamma IIB inhibition of Fc epsilon RI signaling.
    Ott VL; Tamir I; Niki M; Pandolfi PP; Cambier JC
    J Immunol; 2002 May; 168(9):4430-9. PubMed ID: 11970986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
    Redig AJ; Vakana E; Platanias LC
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1():45-53. PubMed ID: 21299459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt.
    Wick MJ; Dong LQ; Hu D; Langlais P; Liu F
    J Biol Chem; 2001 Nov; 276(46):42843-50. PubMed ID: 11551902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
    Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
    Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis.
    Zhao M; Janas JA; Niki M; Pandolfi PP; Van Aelst L
    Mol Cell Biol; 2006 Apr; 26(7):2479-89. PubMed ID: 16537894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.
    Sonoyama J; Matsumura I; Ezoe S; Satoh Y; Zhang X; Kataoka Y; Takai E; Mizuki M; Machii T; Wakao H; Kanakura Y
    J Biol Chem; 2002 Mar; 277(10):8076-82. PubMed ID: 11779872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of bcr-abl in the activation of JAK1 kinase.
    Henderson YC; Guo XY; Greenberger J; Deisseroth AB
    Clin Cancer Res; 1997 Feb; 3(2):145-9. PubMed ID: 9815665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
    Thomas EK; Cancelas JA; Zheng Y; Williams DA
    Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
    Raitano AB; Halpern JR; Hambuch TM; Sawyers CL
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11746-50. PubMed ID: 8524841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Million RP; Van Etten RA
    Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.
    Bandyopadhyay G; Biswas T; Roy KC; Mandal S; Mandal C; Pal BC; Bhattacharya S; Rakshit S; Bhattacharya DK; Chaudhuri U; Konar A; Bandyopadhyay S
    Blood; 2004 Oct; 104(8):2514-22. PubMed ID: 15226183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.